3Benjamin H J, Nikore V, Takagishi J. Practical management:community associated methicillin-resistant Staphylococcus aureus (CA-MRSA) :the latest sports epidemic[J]. Clin J Sport Med, 2007,17(5) : 393-397.
4Tedesco K L,Rybak M J. Daptomycin[J]. Pharmacotherapy, 2004,24(1):41-57.
5Falagas M E,Kasiakou S K. Colistin:the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections[J].Clin Infect Dis,2005,40(9) : 1333-1341.
9Uchino S, Bellomo R, Morimatsu H, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney( B. E. S. T. kidney) investigators [ J ]. Intensive Care Med, 2007, 33(9) :1563-1570.
10Kuang D, Verbine A, Roneo C, et al. Pharmacokinetics and anti - microbial dosing adjustment in critically ill patients during continuous renal replacement therapy [ J]. Clin Nephrel, 2007, 67 (5) :267-284.
